Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Pharmacyclics LLC.
SWOG Cancer Research Network
University of Chicago
Eli Lilly and Company
The Lymphoma Academic Research Organisation
Universität des Saarlandes
Incyte Corporation
Celgene
Janssen Research & Development, LLC
Celgene
University of Liverpool
Mayo Clinic
Cyteir Therapeutics, Inc.
BeiGene
M.D. Anderson Cancer Center
University of Rochester
University of Giessen
Nordic Nanovector
University College, London
City of Hope Medical Center
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
City of Hope Medical Center
Eastern Cooperative Oncology Group
Dr. Reddy's Laboratories Limited
University of Nebraska
University of Nebraska
Hoffmann-La Roche
National Cancer Institute (NCI)
Celgene
University of Nebraska
University of Nebraska
Eastern Cooperative Oncology Group
Hoffmann-La Roche
Abramson Cancer Center at Penn Medicine
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Brown University
Trans Tasman Radiation Oncology Group
Ohio State University Comprehensive Cancer Center
Fondazione Italiana Linfomi - ETS
M.D. Anderson Cancer Center
Alexion Pharmaceuticals, Inc.
CTI BioPharma
National Cancer Institute (NCI)
Universität des Saarlandes
SymBio Pharmaceuticals
Hoffmann-La Roche
Universität des Saarlandes
Universität des Saarlandes